Anti-CD40L (Ruplizumab), Human IgG1 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC |
---|---|
Primary Accession | P29965 |
Reactivity | Human |
Host | Recombinant |
Clonality | Monoclonal |
Isotype | Human IgG1, kappa |
Calculated MW | 29274 Da |
Gene ID | 959 |
---|---|
Alias Symbol | CD40LG |
Other Names | CD40 ligand; tumour necrosis factor ligand superfamily member 5; TNFSF5; CD154; tumour necrosis factor related activation protein; TRAP |
Appearance | Colorless liquid |
Formulation | 200 µg affinity purified human antibody in phosphate-buffered saline (PBS) containing 0.02% Proclin 300 |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | Anti-CD40L (Ruplizumab), Human IgG1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CD40LG |
---|---|
Synonyms | CD40L, TNFSF5, TRAP |
Function | Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Costimulates T-cell proliferation and cytokine production (PubMed:8617933). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity). |
Cellular Location | Cell membrane; Single-pass type II membrane protein. Cell surface |
Tissue Location | Specifically expressed on activated CD4+ T- lymphocytes |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cytokine that binds to CD40/TNFRSF5. Costimulates T-cell proliferation and cytokine production. Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2 in T-cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4. Involved in immunoglobulin class switching. The antibody binds specifically to CD40L, a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. The antibody neutralizes CD40L function, as it blocks the interaction between CD40 and CD40L. When injected into cynomolgus monkeys, the antibody was found to have a T1/2 of 531 ± 155 hours.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.